FDA oncology advisory committee to weigh Exelixis' Cabometyx in neuroendocrine tumors

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee (ODAC) in March 2025.